top
Search terms
Results 1 - 10 of 16 - ordered by :
Pages: 1 2
Ehjcvp

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER The aim of this study was to use individual ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Articles, Björn W. Karlson, Olov Wiklund, Michael K. Palmer, Stephen J. Nicholls, Pia Lundman, Philip J. Barter

Date : 01/10/2016 Item size : 168264 bytes
Ehjcvp

Given the burden of cardiovascular disease in patients with diabetes, the focus should shift towards cardiovascular outcome studies designed to evaluate efficacy (i.e. to determine the efficacy of a ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Faiez Zannad, Wendy Gattis Stough, Raymond J. Lipicky, Juan Tamargo, George L. Bakris, Jeffrey S. Borer, Maria de los Angeles Alonso ...

Date : 01/07/2016 Item size : 285307 bytes
Ehjcvp

Significant evidence demonstrated that atherosclerotic plaques are not passive collections of lipids, but sites of active interactions between cells of the immune system and vascular cells that ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Jessica Bullenkamp, Sip Dinkla, Juan Carlos Kaski, Ingrid E. Dumitriu

Date : 01/07/2016
Ehjcvp

Various studies have now raised hope for an additional protective effect of pharmacological DPP4 inhibition in vascular diseases. Besides GLP1, especially, the inhibition of SDF1 cleavage has been ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Friederike Remm, Wolfgang-Michael Franz, Christoph Brenner

Date : 01/07/2016
Ehjcvp

Abstract Aims An important decision in the management of patients with atrial fibrillation is whether to adopt a rate or rhythm control strategy. Methods and results We conducted a retrospective ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Carl Hayward, Hitesh C. Patel, Ketna Patel, Carlo Di Mario, Alexander R. Lyon, Syed Y. Ahsan, Edward Rowland

Date : 01/04/2016 Item size : 222623 bytes
Ehjcvp

Furthermore, it is noteworthy that the lack of a carboxyl terminus renders CNP highly susceptible to cleavage by neprilysin (NEP).6 Physiologically CNP via activation of pGC-B exhibits antifibrotic ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Johann Wojta

Date : 01/04/2016 Item size : 144952 bytes
Ehjcvp

Introduction Cenderitide (CD-NP) is a novel chimeric natriuretic peptide (NP) currently in clinical trials for heart failure (HF).13 As a chimeric peptide, cenderitide is a single-chemical entity ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Candace Y.W. Lee, Brenda K. Huntley, Daniel J. McCormick, Tomoko Ichiki, S. Jeson Sangaralingham, Ondrej Lisy, John C. ...

Date : 01/04/2016
Ehjcvp

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER The aim of this study was to use individual ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Björn W. Karlson, Olov Wiklund, Michael K. Palmer, Stephen J. Nicholls, Pia Lundman, Philip J. Barter

Date : 29/03/2016 Item size : 169375 bytes
Ehjcvp

Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Nucleus composition Chairperson Stefan Agewall, Norway Vice-chairperson Basil S. Lewis, Israel ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Basil S. Lewis, Stefan Agewall

Date : 01/01/2016 Item size : 109861 bytes
Ehjcvp

[...]the three pivotal clinical trials investigating the use of beta-blockers in HF (CIBIS II, COPERNICUS, and MERIT-HF) showed an approximate 34% relative reduction in mortality.13 ACE inhibitors ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Massimo Volpe, Pietro Francia

Date : 01/07/2015